UPDATED: Serina Therapeutics Congratulates Juvenescence Ltd. on $76M First Tranche Close of Series B Funding and Strategic Partnership with M42

Core Insights - Serina Therapeutics, Inc. has announced a strategic partnership with Juvenescence Ltd., which has successfully closed the first tranche of a $76 million Series B financing round, targeting a total of $150 million [2][3] - The partnership aims to establish a drug development hub in Abu Dhabi, integrating AI-enabled drug discovery with advanced clinical infrastructure to expedite the development of innovative therapeutics [3][4] - Serina is focused on developing its proprietary POZ Platform™ for drug optimization, targeting neurological diseases and other indications, and is positioned as a core portfolio company of Juvenescence [5][4] Company Overview - Serina Therapeutics is a clinical-stage biotechnology company headquartered in Huntsville, Alabama, specializing in drug candidates for neurological diseases and other conditions [5] - The POZ Platform™ developed by Serina has the potential to enhance the efficacy and safety profiles of various therapeutic modalities, including small molecules and RNA-based therapeutics [5] - Juvenescence, the strategic partner, is an AI-enabled biotech company focused on developing medicines to extend healthy lifespan by targeting aging mechanisms [7][9] Strategic Partnerships - The collaboration between Juvenescence and M42, a global health company based in Abu Dhabi, signifies a commitment to building a leading life-sciences hub and developing a pipeline of innovative therapeutics [4][11] - M42 operates over 480 facilities across 26 countries and employs more than 20,000 people, integrating advanced technologies in healthcare [12]